
Fennec Pharmaceuticals Inc.: shareholders and insiders
Price
$13.33
November 18, 2026Market cap $460M
What Ploutos Investor adds for Fennec Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($10.90 then, $13.33 on Nov 18, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 16, 2026, from their own Form 4 filings.
Insider trades start on May 2, 2007
Until lately Fennec Pharmaceuticals was a foreign company listed in the US. Officers of foreign companies do not report their purchases and sales, so there are none before. They are not missing on our side: they were never filed.
- Until 2007Foreign company (annual report on 20-F)
- March 2008Becomes a US filer (annual report on 10-K)
- May 2, 2007The first insider trade report (Form 4)
Bought on the market
–
nobody
Sold on the market
$9.9M
6 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan22%
- The rest78%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $2.3M by 5 people
- 2025: no buys, sold $7.6M by 2 people
- 2026: no buys, sold $2.3M by 5 people
- Nov 13, 2026Marco Maria BrugheraDirectorKind10b5-1
- Nov 13, 2026Marco Maria BrugheraDirectorKind10b5-1
- Oct 31, 2026Terry L EvansChief Commercial OfficerKind
- Oct 31, 2026Pierre Sargis SayadChief Medical OfficerKind
- Oct 31, 2026Jeffrey S. HackmanChief Executive OfficerKind
- Oct 31, 2026Christiana Marie CioffiChief Strategy OfficerKind
- Oct 31, 2026Robert AndradeCHIEF FINANCIAL OFFICERKind
- Oct 12, 2026Pierre Sargis SayadChief Medical OfficerKind
- Oct 12, 2026Jeffrey S. HackmanChief Executive OfficerKind
- Oct 12, 2026Terry L EvansChief Commercial OfficerKind
- Oct 12, 2026Christiana Marie CioffiChief Strategy OfficerKind
- Oct 12, 2026Robert AndradeCHIEF FINANCIAL OFFICERKind
- Sep 30, 2026Pierre Sargis SayadChief Medical OfficerKind
- Sep 30, 2026Terry L EvansChief Commercial OfficerKind
- Sep 30, 2026Jeffrey S. HackmanChief Executive OfficerKind
- Sep 30, 2026Christiana Marie CioffiChief Strategy OfficerKind
- Sep 30, 2026Robert AndradeCHIEF FINANCIAL OFFICERKind
- Sep 15, 2026Marco Maria BrugheraDirectorKind10b5-1
- Sep 15, 2026Marco Maria BrugheraDirectorKind10b5-1
- Sep 1, 2026Rosty RaykovKind10b5-1
- Aug 31, 2026Rosty RaykovKind10b5-1
- Aug 31, 2026Pierre Sargis SayadChief Medical OfficerKind
- Aug 31, 2026Pierre Sargis SayadChief Medical OfficerKind
- Aug 31, 2026Terry L EvansChief Commercial OfficerKind
- Aug 31, 2026Christiana Marie CioffiChief Strategy OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Marco Maria BrugheraDirector | 10b5-1 | 20.0K | $2.11 | $42.2K | Form 4 |
| Nov 13, 2026 | Marco Maria BrugheraDirector | 10b5-1 | 20.0K | $12.00 | $240.0K | Form 4 |
| Oct 31, 2026 | Terry L EvansChief Commercial Officer | 168 | – | – | Form 4 | |
| Oct 31, 2026 | Pierre Sargis SayadChief Medical Officer | 168 | – | – | Form 4 | |
| Oct 31, 2026 | Jeffrey S. HackmanChief Executive Officer | 1,159 | – | – | Form 4 | |
| Oct 31, 2026 | Christiana Marie CioffiChief Strategy Officer | 156 | – | – | Form 4 | |
| Oct 31, 2026 | Robert AndradeCHIEF FINANCIAL OFFICER | 1,703 | – | – | Form 4 | |
| Oct 12, 2026 | Pierre Sargis SayadChief Medical Officer | 3,846 | $5.53 | $21.3K | Form 4 | |
| Oct 12, 2026 | Jeffrey S. HackmanChief Executive Officer | 2,224 | $5.53 | $12.3K | Form 4 | |
| Oct 12, 2026 | Terry L EvansChief Commercial Officer | 2,326 | $5.53 | $12.9K | Form 4 | |
| Oct 12, 2026 | Christiana Marie CioffiChief Strategy Officer | 3,946 | $5.53 | $21.8K | Form 4 | |
| Oct 12, 2026 | Robert AndradeCHIEF FINANCIAL OFFICER | 3,846 | $5.53 | $21.3K | Form 4 | |
| Sep 30, 2026 | Pierre Sargis SayadChief Medical Officer | 168 | – | – | Form 4 | |
| Sep 30, 2026 | Terry L EvansChief Commercial Officer | 168 | – | – | Form 4 | |
| Sep 30, 2026 | Jeffrey S. HackmanChief Executive Officer | 1,159 | – | – | Form 4 | |
| Sep 30, 2026 | Christiana Marie CioffiChief Strategy Officer | 156 | – | – | Form 4 | |
| Sep 30, 2026 | Robert AndradeCHIEF FINANCIAL OFFICER | 1,703 | – | – | Form 4 | |
| Sep 15, 2026 | Marco Maria BrugheraDirector | 10b5-1 | 15.5K | $2.11 | $32.8K | Form 4 |
| Sep 15, 2026 | Marco Maria BrugheraDirector | 10b5-1 | 15.5K | $10.29 | $160.0K | Form 4 |
| Sep 1, 2026 | Rosty Raykov | 10b5-1 | 10.0K | $12.11 | $121.1K | Form 4 |
| Aug 31, 2026 | Rosty Raykov | 10b5-1 | 2,778 | – | – | Form 4 |
| Aug 31, 2026 | Pierre Sargis SayadChief Medical Officer | 168 | – | – | Form 4 | |
| Aug 31, 2026 | Pierre Sargis SayadChief Medical Officer | 12.0K | $12.18 | $146.2K | Form 4 | |
| Aug 31, 2026 | Terry L EvansChief Commercial Officer | 168 | – | – | Form 4 | |
| Aug 31, 2026 | Christiana Marie CioffiChief Strategy Officer | 156 | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 1, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by FENC's officers and directors from 2010 up to November 18, 2025, 16 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 11 more, back to 2010
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Rosalind Advisors, Inc.with 3 more personsCommon SharesShare of class9.60%
- Sonic Fund II, L.P.with 2 more personsShare of class8.20%
- Orin Hirschmanwith 1 more personCommon Shares, no par valueShare of class7.10%
- Solas Capital Management, LLCwith 1 more personCommon Shares, no par valueShare of class5.40%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc.with 3 more personsCommon Shares | 9.60% | 3.32M | Aug 13, 20264 filings since Nov 13, 2025 | 13G/A | |
| Sonic Fund II, L.P.with 2 more persons | 8.20% | 2.80M | Feb 17, 2026 | 13G/A | |
| Orin Hirschmanwith 1 more personCommon Shares, no par value | 7.10% | 2.50M | Oct 19, 20262 filings since Apr 28, 2026 | 13G/A | |
| Solas Capital Management, LLCwith 1 more personCommon Shares, no par value | 5.40% | 1.89M | Aug 14, 20264 filings since Nov 14, 2024 | 13G/A |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter-41%
- Citadel Advisors (Griffin)In the quarter+133%
- Millennium Mgmt (Englander)In the quarter+41%
- Renaissance TechnologiesIn the quarter+2.4%
- AQR CapitalIn the quarter+1.0%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 33.4K | -41% | $400.0K | 0.00% |
| Citadel Advisors (Griffin) | 165.8K | +133% | $1.8M | 0.00% |
| Millennium Mgmt (Englander) | 37.2K | +41% | $400.0K | 0.00% |
| Renaissance Technologies | 137.4K | +2.4% | $1.5M | 0.00% |
| AQR Capital | 93.8K | +1.0% | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.41% of its shares outstanding were held short, -5.0% since the report before.
- Shares held short
- 487.5K
- 1.41%
- Since the report before513.3K on Sep 30, 2026
- -5.0%
- 3.8
- 129.1K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 45%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.92M
- Nov 15, 2023: Shares held short 1.96M
- Nov 30, 2023: Shares held short 1.91M
- Dec 15, 2023: Shares held short 2.04M
- Dec 29, 2023: Shares held short 2.01M
- Jan 12, 2024: Shares held short 1.86M
- Jan 31, 2024: Shares held short 1.79M
- Feb 15, 2024: Shares held short 1.75M
- Feb 29, 2024: Shares held short 1.71M
- Mar 15, 2024: Shares held short 1.69M
- Mar 28, 2024: Shares held short 1.81M
- Apr 15, 2024: Shares held short 1.87M
- Apr 30, 2024: Shares held short 1.81M
- May 15, 2024: Shares held short 1.74M
- May 31, 2024: Shares held short 1.77M
- Jun 14, 2024: Shares held short 1.77M
- Jun 28, 2024: Shares held short 1.80M
- Jul 15, 2024: Shares held short 1.95M
- Jul 31, 2024: Shares held short 1.94M
- Aug 15, 2024: Shares held short 1.91M
- Aug 30, 2024: Shares held short 1.84M
- Sep 13, 2024: Shares held short 1.84M
- Sep 30, 2024: Shares held short 1.85M
- Oct 15, 2024: Shares held short 1.84M
- Oct 31, 2024: Shares held short 1.78M
- Nov 15, 2024: Shares held short 1.87M
- Nov 29, 2024: Shares held short 2.10M
- Dec 13, 2024: Shares held short 2.11M
- Dec 31, 2024: Shares held short 1.98M
- Jan 15, 2025: Shares held short 2.00M
- Jan 31, 2025: Shares held short 1.95M
- Feb 14, 2025: Shares held short 2.04M
- Feb 28, 2025: Shares held short 1.93M
- Mar 14, 2025: Shares held short 1.44M
- Mar 31, 2025: Shares held short 1.50M
- Apr 15, 2025: Shares held short 1.44M
- Apr 30, 2025: Shares held short 1.45M
- May 15, 2025: Shares held short 1.51M
- May 30, 2025: Shares held short 1.42M
- Jun 13, 2025: Shares held short 1.36M
- Jun 30, 2025: Shares held short 1.31M
- Jul 15, 2025: Shares held short 1.30M
- Jul 31, 2025: Shares held short 1.28M
- Aug 15, 2025: Shares held short 1.28M
- Aug 29, 2025: Shares held short 1.25M
- Sep 15, 2025: Shares held short 1.33M
- Sep 30, 2025: Shares held short 1.30M
- Oct 15, 2025: Shares held short 1.31M
- Oct 31, 2025: Shares held short 980.9K
- Nov 14, 2025: Shares held short 1.07M
- Nov 28, 2025: Shares held short 882.2K
- Dec 15, 2025: Shares held short 859.1K
- Dec 31, 2025: Shares held short 777.9K
- Jan 15, 2026: Shares held short 741.6K
- Jan 30, 2026: Shares held short 769.5K
- Feb 13, 2026: Shares held short 811.6K
- Feb 27, 2026: Shares held short 824.3K
- Mar 13, 2026: Shares held short 806.6K
- Mar 31, 2026: Shares held short 913.3K
- Apr 15, 2026: Shares held short 930.6K
- Apr 30, 2026: Shares held short 1.06M
- May 15, 2026: Shares held short 623.4K
- May 29, 2026: Shares held short 498.1K
- Jun 15, 2026: Shares held short 450.6K
- Jun 30, 2026: Shares held short 488.7K
- Jul 15, 2026: Shares held short 609.2K
- Jul 31, 2026: Shares held short 615.9K
- Aug 14, 2026: Shares held short 532.1K
- Aug 31, 2026: Shares held short 520.7K
- Sep 15, 2026: Shares held short 545.0K
- Sep 30, 2026: Shares held short 513.3K
- Oct 15, 2026: Shares held short 487.5K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading34.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 34.5% of the shares in the reported trades were short sales, against 32.9% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 34.5%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 32.9%
- Change
- +1.6 pts
- Short sales a dayon average, of 153.0K shares
- 52.7K
- More than atof 3,656 US-listed companies, same days
- 10%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 39.5%
- Oct 13, 2026: Short sales 13.8%
- Oct 14, 2026: Short sales 27.2%
- Oct 15, 2026: Short sales 50.5%
- Oct 16, 2026: Short sales 43.4%
- Oct 19, 2026: Short sales 44.7%
- Oct 20, 2026: Short sales 29.9%
- Oct 21, 2026: Short sales 45.4%
- Oct 22, 2026: Short sales 17.4%
- Oct 23, 2026: Short sales 46.5%
- Oct 26, 2026: Short sales 43.6%
- Oct 27, 2026: Short sales 51.1%
- Oct 28, 2026: Short sales 23%
- Oct 29, 2026: Short sales 34.7%
- Oct 30, 2026: Short sales 34.5%
- Nov 2, 2026: Short sales 50.9%
- Nov 3, 2026: Short sales 39.8%
- Nov 4, 2026: Short sales 27%
- Nov 5, 2026: Short sales 48.6%
- Nov 6, 2026: Short sales 61.7%
- Nov 9, 2026: Short sales 36.6%
- Nov 10, 2026: Short sales 33.5%
- Nov 11, 2026: Short sales 39%
- Nov 12, 2026: Short sales 35%
- Nov 13, 2026: Short sales 32.1%
- Nov 16, 2026: Short sales 38.3%
- Nov 17, 2026: Short sales 29.3%
- Nov 18, 2026: Short sales 19.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Southpoint GP, LLCTenPercentOwnerDirectly–
- Southpoint Capital Advisors LLCTenPercentOwnerDirectly–
- Southpoint Capital Advisors LPTenPercentOwnerDirectly–
- Robert AndradeCHIEF FINANCIAL OFFICERDirectly248.6K
- Rosty RaykovOtherDirectly124.4K
- Jeffrey S. HackmanChief Executive OfficerDirectly70.8K
- Chris A RallisDirectorDirectly63.1K
- Christiana Marie CioffiChief Strategy OfficerDirectly28.9K
- Terry L EvansChief Commercial OfficerDirectly24.2K
- Pierre Sargis SayadChief Medical OfficerDirectly13.7K
- Marco Maria BrugheraDirectorDirectly–
- Adrian HaighCHIEF OPERATING OFFICERDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Southpoint GP, LLCTenPercentOwner | – | 3.76M | Nov 17, 2025 | Form 4 |
| Southpoint Capital Advisors LLCTenPercentOwner | – | 3.74M | Nov 18, 2025 | Form 4 |
| Southpoint Capital Advisors LPTenPercentOwner | – | 2.74M | Dec 24, 2025 | Form 4 |
| Robert AndradeCHIEF FINANCIAL OFFICER | 248.6K | – | Oct 31, 2026 | Form 4 |
| Rosty RaykovOther | 124.4K | – | Sep 1, 2026 | Form 4 |
| Jeffrey S. HackmanChief Executive Officer | 70.8K | – | Oct 31, 2026 | Form 4 |
| Chris A RallisDirector | 63.1K | – | May 11, 2026 | Form 4 |
| Christiana Marie CioffiChief Strategy Officer | 28.9K | – | Oct 31, 2026 | Form 4 |
| Terry L EvansChief Commercial Officer | 24.2K | – | Oct 31, 2026 | Form 4 |
| Pierre Sargis SayadChief Medical Officer | 13.7K | – | Oct 31, 2026 | Form 4 |
| Marco Maria BrugheraDirector | – | – | Nov 13, 2026 | Form 4 |
| Adrian HaighCHIEF OPERATING OFFICER | – | – | Apr 22, 2024 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.07%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
5 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 84
- Q4 2025: Managers 96
- Q1 2026: Managers 91
- Q2 2026: Managers 105
Institutional investors by quarter
The fund managers holding FENC, quarter by quarter, from Q3 2017 to Q2 2025, 32 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 105 managers held 16.31M shares, worth $175M. During the quarter 25 opened a position, 11 closed one, 42 added and 18 trimmed.
The largest holders, Q2 2026
- Rosalind AdvisorsIn the quarter+9.6%
- AIGH Capital ManagementIn the quarter+25%
- Solas Capital ManagementIn the quarter-24%
- BlackRockIn the quarter+26%
- AWM InvestmentIn the quarter+61%
- Vanguard Capital ManagementIn the quarter-6.4%
- Prospect Capital AdvisorsIn the quarter
- State StreetIn the quarter+19%
- Geode Capital ManagementIn the quarter+8.3%
- Jane Street GroupIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Rosalind Advisors | 3.19M | +9.6% | $34M |
| AIGH Capital Management | 2.49M | +25% | $27M |
| Solas Capital Management | 1.89M | -24% | $20M |
| BlackRock | 1.73M | +26% | $19M |
| AWM Investment | 1.16M | +61% | $12M |
| Vanguard Capital Management | 839.3K | -6.4% | $9.0M |
| Prospect Capital Advisors | 497.8K | $5.4M | |
| State Street | 426.0K | +19% | $4.6M |
| Geode Capital Management | 402.6K | +8.3% | $4.3M |
| Jane Street Group | 233.9K | $2.5M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Fennec Pharmaceuticals's filings show?
Who buys and sells is one part of Fennec Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have FENC's insiders bought or sold?
From Jun 1, 2026 to Nov 16, 2026 Fennec Pharmaceuticals's insiders bought 0 and sold $1.8M of shares on the market. 92% of the sales were under set 10b5-1 plans.
Which well-known managers hold FENC?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $1.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.